The INNO-LiPA HBV DR v2 assay is designed to detect hepatitis B virus mutations conveying resistance to lamivudine and adefovir. Our study confirms that this assay can simultaneously detect the presence of lamivudine and adefovir resistance mutations in clinical samples, has a high degree of concordance with sequencing, and can detect mutants earlier.
Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir / Hussain M.; Fung S.; Libbrecht E.; Sablon E.; Cursaro C.; Andreone P.; Lok A.S.. - In: JOURNAL OF CLINICAL MICROBIOLOGY. - ISSN 0095-1137. - ELETTRONICO. - 44:(2006), pp. 1094-1097. [10.1128/JCM.44.3.1094-1097.2006]
Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir.
ANDREONE, PIETRO;
2006
Abstract
The INNO-LiPA HBV DR v2 assay is designed to detect hepatitis B virus mutations conveying resistance to lamivudine and adefovir. Our study confirms that this assay can simultaneously detect the presence of lamivudine and adefovir resistance mutations in clinical samples, has a high degree of concordance with sequencing, and can detect mutants earlier.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
